Navigation Links
Infant Blood May Provide Insights into Diseases Present at Birth
Date:12/15/2008

GRAND RAPIDS, Mich., Dec. 15 /PRNewswire/ -- Van Andel Institute (VAI) researchers are the first to apply a new technology to measure on a large scale the presence of genes in blood spots - the blood drawn from newborn infants to screen for health-threatening conditions. Using a random sample of blood spots collected from 1998 to 2004 and the latest RNA technology, researchers were able to detect over 3,000 genes in each sample, and to quantify the levels of several specific genes. This type of testing and data could eventually be used for the retrospective study of disease with an ultimate goal of identifying at-risk children in an attempt to pre-empt the onset of disease.

"This is a vast, underutilized resource," said James Resau, Ph.D., distinguished scientific investigator, deputy director for special programs, and director of the Division of Quantitative Sciences at VAI. "Imagine testing blood from nearly the entire population of U.S. infants and using the data for the retrospective study of disease. If a particular disease pops up in a specific segment of the population, you could use the data to look for causes, biomarkers and potential drug targets."

All 50 states in the U.S. have mandatory newborn screening programs, and the practice has been adopted by most countries around the world. Typically, this involves pricking the heel of newborns, also known as a "heel stick," to get a few drops of blood on filter paper. The blood is then screened for diseases for which early diagnosis and therapy can cure, prevent, or lessen the effects of the disease. The list of diseases tested for varies by state, but testing generally only uses a small portion of the blood. The rest is archived in varying conditions, sometimes for 21 years or more.

"The amazing thing is that many of these blood spots are stored in room temperature conditions, so we're basically testing dried blood on filter paper," said Resau. "Even so, we got good RNA test results from samples that have been in storage for as long as nine years."

While other researchers have confirmed the stability of blood spot RNA and its ability to reflect diseases, VAI researchers are the first to apply the latest tools in RNA technology to measure the expression of genes in blood spots on a larger scale. Using a random sample of blood spots collected from 1998 to 2004, researchers were able to detect an average of 3,480 genes in each sample, and to quantify the levels of several specific genes. Researchers in VAI's Laboratories of Microarray Technology and Molecular Epidemiology led by Resau and lead author of the study, Peterson T. Haak, received valuable assistance and expertise from Nigel Paneth, M.D., and his colleagues at Michigan State University's College of Human Medicine, College of Osteopathic Medicine and Department of Physiology.

"By teaming with state health departments and utilizing existing blood spot archives, we hope to improve our understanding of diseases that are not immediately apparent at birth, but have roots in the perinatal period," said Resau. "Measuring the relative abundance of thousands of expressed genes from

universally collected neonatal blood spots may open new avenues of research into perinatal markers and determinants of disease development."

By state law in effect since 1986, the Michigan Department of Community Health stores blood spots for 21.5 years. Michigan state law explicitly encourages the use of these archived blood spots for medical research; anonymous samples can be obtained for research with approval from an Institutional Review Board and the Michigan Department of Public Health, and individually identified samples can be obtained with parental informed consent.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.


Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
James Resau
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81557


'/>"/>
SOURCE Van Andel Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
2. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
3. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill
4. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
5. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
6. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
7. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
8. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
9. Pregnant Women Need Omega-3 to Boost Infant Development
10. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
11. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):